Literature DB >> 2374246

Cyclosporine inhibits the development of medial thickening after experimental arterial injury.

M Wengrovitz1, L G Selassie, R R Gifford, B L Thiele.   

Abstract

Vascular proliferative lesions may occur after arterial injury and consist of inflammatory cells and proliferating smooth muscle cells. We studied the effect of cyclosporine on modulating the response to experimental arterial injury in rats. Arterial injury was created in 90 rats by rotating a 1 mm coronary dilator in the right common iliac artery. After treatment with parenteral cyclosporine 2 mg/kg/day or 5 mg/kg/day, or with saline solution, right and left iliac arteries were perfusion fixed and cross sectioned. The thickness of the tunica media was measured, and the groups were compared with a Student's t test. In the control groups the injured iliac artery had significant medial thickening when compared to the noninjured (p less than 0.05) from 1 to 42 days after injury. Injured arteries treated with cyclosporine 2 mg/kg/day for 14 days showed significantly less medial thickening when compared to controls (p less than 0.01). Cyclosporine 5 mg/kg/day for 14, 28, and 42 days showed a significant inhibition of medial thickening (p less than 0.05) for each time period. These results show that cyclosporine affects the response to experimental arterial injury by inhibiting the development of medial thickening. The most consistent effects were seen with a cyclosporine dose of 5 mg/kg/day for 2 to 6 weeks. These data also provide further evidence that immunologic mechanisms may modulate vascular proliferative lesions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2374246

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  1 in total

1.  Expression of cell cycle regulators during smooth muscle cell proliferation after balloon catheter injury of rat artery.

Authors:  Jung Kee Chung; Taeseung Lee; In Mok Jung; Young Kyun Kim; Seung Kee Min; Jeong Wook Suh; Sang Joon Kim
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.